Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

Enanta Pharmaceuticals files patent for 17ß-HSD13 inhibitors for treating metabolic disease - March 12

Enanta Pharmaceuticals. has filed a patent for compounds of Formula (I) as 17ß-HSD13 inhibitors for treating metabolic diseases** and liver conditions. The patent claim includes a compound represented by Formula I or its pharmaceutically acceptable salt or ester.

Furthermore, the patent application describes methods for preventing or treating 17ß-HSD13 mediated diseases or conditions in individuals by administering a therapeutically effective amount of the compound. The diseases or conditions targeted include nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC). The use of the compound in the manufacture of medicaments for these specific diseases is also claimed, emphasizing the potential therapeutic applications of the disclosed compound.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-files-patent-for-17-hsd13-inhibitors-for-treating-metabolic-disease/

**Metabolic disorders: Types, causes, and symptoms -
Examples of metabolic disorders include diabetes, Gaucher's disease, and hemochromatosis. Symptoms can include tiredness, weight loss or gain, and nausea and vomiting. Metabolism is a term that describes the biochemical processes that allow people to grow, reproduce, repair damage, and respond to their environment.